TTetraneuron — Seed (estimated) · approximately €2.5M
Tetraneuron is developing a gene therapy for Alzheimer's disease. It raised more than €2.5M from unnamed investors specialised in biopharma and advanced therapies, with Borealis Corporate Finance advising; no stage was given.
Lead not disclosed
RoundSeed (estimated)
Announced19 Jun 2021
CityMadrid · reported Valencia
SectorHealthtech & Bio · Biotech
Source
E
E
The company
Investors
No investors were disclosed for this round.